Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 101,658 shares, an increase of 3,995.8% from the May 31st total of 2,482 shares. Based on an average daily trading volume, of 583,559 shares, the short-interest ratio is currently 0.2 days. Currently, 4.4% of the company’s shares are short sold.

Aptorum Group Stock Down 1.5%

APM stock traded down $0.01 during midday trading on Friday, reaching $0.77. 32,663 shares of the company were exchanged, compared to its average volume of 371,941. Aptorum Group has a 1-year low of $0.65 and a 1-year high of $4.47. The stock’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $0.93.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.